FDA's Retroactive Use Of PMA Data Violates FDAMA, HIMA Petition Says
This article was originally published in The Gray Sheet
Executive Summary
FDA violated the FDA Modernization Act by applying retroactively a provision of the law relating to use of data from approved premarket approval applications, the Health Industry Manufacturers Association maintains in an Aug. 9 citizen petition.
You may also be interested in...
"Six-Year Rule" On Access To PMA Data Applies To All PMAs Since 1990
FDA's decision to apply the FDA Modernization Act's "six-year rule" to premarket approval applications approved prior to enactment of the statute is consistent with a "least burdensome" approach, the agency maintains.
"Six-Year Rule" On Access To PMA Data Applies To All PMAs Since 1990
FDA's decision to apply the FDA Modernization Act's "six-year rule" to premarket approval applications approved prior to enactment of the statute is consistent with a "least burdensome" approach, the agency maintains.
Extracorporeal shock wave lithotripters
FDA proposed rule published Feb. 8 would reclassify the devices from Class III to Class II when intended to fragment kidney and ureteral calculi. A draft guidance released by the agency the same day would serve as a special control for the devices. According to the document, 510(k)s for lithotripters with mechanisms of action and shock wave characteristics similar to existing devices would require data from 20 patients at two sites. The stipulation is in line with a recommendation made by FDA's Gastroenterology and Urology Devices Panel in July ("The Gray Sheet" Aug. 3, 1998, p. 8)